Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium alpha-ketoisocaproate is a calcium salt of the alpha-keto acid analogue of the essential amino acid leucine. In the management of chronic kidney disease (CKD), it is used to provide the carbon skeleton of leucine without the associated nitrogen load. Upon ingestion, the molecule undergoes transamination, a process where it picks up a nitrogen group from waste products like urea or non-essential amino acids to form L-leucine. This mechanism helps to recycle nitrogenous waste, thereby reducing blood urea nitrogen (BUN) levels and slowing the progression of renal dysfunction. Additionally, the calcium component helps address mineral imbalances common in CKD, such as hyperphosphatemia. It is typically administered as part of a restricted protein diet to maintain nutritional status while minimizing uremic symptoms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium alpha-ketoisocaproate.